News & Events
Tuesday, January 29, 2013
FDA Grants Soligenix Fast Track Designation for OrbeShield™ for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
[read more]Monday, January 07, 2013
BARDA Invites Soligenix to Submit Contract Proposal for Development of OrbeShield™ in GI ARS
[read more]Friday, January 04, 2013
Soligenix Receives IND Clearance from FDA to Initiate Program Evaluating OrbeShield™ as a Therapy for Gastrointestinal Acute Radiation Syndrome
[read more]Wednesday, January 02, 2013
FDA Grants Soligenix Orphan Drug Designation for OrbeShieldTM for Treatment after Exposure to a Radiological Disaster
[read more]Friday, December 28, 2012
Soligenix Receives $521,000 in Non-Dilutive Financing from New Jersey’s Technology Business Tax Certificate Transfer Program
[read more]Thursday, December 27, 2012
Soligenix Regains North American and European Commercial Rights to Oral BDP
[read more]Tuesday, December 18, 2012
Soligenix Expands Pipeline with Acquisition of Novel Innate Defense Regulator Clinical Program
[read more]Wednesday, November 14, 2012
Soligenix Reports Third Quarter 2012 Financial Results and Highlights Recent Accomplishments
[read more]Thursday, November 08, 2012
FDA Grants Soligenix Fast Track Designation for SGX203 for the Treatment of Pediatric Crohn’s Disease
[read more]Wednesday, October 03, 2012
Soligenix Announces Formation of Acute Radiation Syndrome Scientific Advisory Board
[read more]Monday, October 01, 2012
Soligenix Announces Presentation of OrbeShieldTM Data at Annual Radiation Research Society Meeting
[read more]Thursday, September 13, 2012
Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
[read more]Thursday, September 06, 2012
Soligenix Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate SGX203 as Therapy for Pediatric Crohn’s Disease
[read more]Tuesday, September 04, 2012
Soligenix Announces $300,000 NCI SBIR Grant Award Supporting a Phase 2 Trial of orBec® as a Treatment for Chronic GI GVHD
[read more]Tuesday, September 04, 2012
Soligenix CEO talks about the business' present and future (NJ.com article)
[read more]Thursday, August 30, 2012
Soligenix Announces Positive Phase 1B Clinical Results with RiVaxTM, its Vaccine Against Ricin Toxin Exposure
[read more]Friday, August 10, 2012
Soligenix Reports Second Quarter 2012 Financial Results and Highlights Recent Accomplishments
[read more]Tuesday, July 17, 2012
Soligenix Announces $600,000 NIAID SBIR Grant Award Supporting Further Evaluation of OrbeShieldTM as a Treatment for Acute Radiation Syndrome
[read more]Wednesday, June 27, 2012
Soligenix Announces Collaboration with Infectious Disease Research Institute to Develop Thermostabilized Biodefense Vaccines Utilizing Novel Adjuvants
[read more]Monday, May 14, 2012
Soligenix Reports First Quarter 2012 Financial Results and Highlights Recent Accomplishments
[read more]Wednesday, April 25, 2012
Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
[read more]Wednesday, March 28, 2012
Soligenix Reports Year-End 2011 Financial Results and Highlights Recent Accomplishments
[read more]Wednesday, February 22, 2012
Soligenix Announces Positive Survival Results of SGX202 in Radiation Injury
[read more]Friday, February 10, 2012
Soligenix Announces Results from its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
[read more]Monday, February 06, 2012
Soligenix Demonstrates Positive Proof of Concept with its Proprietary Vaccine Thermostabilization Technology
[read more]Tuesday, January 31, 2012
Soligenix Announces 1 for 20 Reverse-Split of its Common Stock
[read more]Thursday, January 26, 2012
Soligenix Receives $574,000 in Non-Dilutive Financing from New Jersey’s Technology Business Tax Certificate Transfer Program
[read more]Wednesday, January 18, 2012
Soligenix Demonstrates Robust Stability Results with its SGX204 Anthrax Vaccine
[read more]Thursday, December 15, 2011
Soligenix Initiates Next Generation Anthrax Vaccine Development Program under Agreement with Harvard University
[read more]Monday, December 12, 2011
Soligenix Announces Publication of Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
[read more]Monday, November 14, 2011
Soligenix Reports Third Quarter 2011 Financial Results
[read more]Tuesday, October 11, 2011
Soligenix Announces Formation of Pediatric Crohn’s Disease Medical Advisory Board
[read more]Thursday, September 15, 2011
Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
[read more]Friday, August 12, 2011
Soligenix Reports Second Quarter 2011 Financial Results and Reviews Accomplishments
[read more]Thursday, July 28, 2011
Soligenix Announces Expansion of Partnership with Sigma-Tau Pharmaceuticals for orBec® in Europe
[read more]Monday, June 27, 2011
Soligenix Announces Appointment of Jerome Zeldis, MD, PhD and Keith Brownlie, CPA to its Board of Directors
[read more]Thursday, June 02, 2011
Soligenix Appoints Joseph Warusz as Vice President of Administration and Controller
[read more]Tuesday, March 29, 2011
Soligenix Reports Year-End 2010 Financial Results and
Highlights Recent Accomplishments
[read more]Wednesday, February 09, 2011
Soligenix to Present at 13th Annual BIO CEO & Investor Conference
[read more]Tuesday, February 01, 2011
Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer
[read more]Thursday, January 27, 2011
Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
[read more]Tuesday, January 25, 2011
Soligenix Receives $245,810 in Non-Dilutive Financing from New Jersey’s Technology Business Tax Certificate Transfer Program
[read more]Friday, January 21, 2011
Soligenix Receives FDA Orphan Drug Designation for RiVaxTM for the Prevention of Ricin Intoxication
[read more]Tuesday, January 18, 2011
Soligenix Announces Positive Preliminary Results of SGX202
in Radiation Injury
[read more]Monday, November 22, 2010
Soligenix Announces Issuance of United States Patent for RiVax™, its Vaccine against Ricin Toxin
[read more]Friday, November 12, 2010
Soligenix Reports Third Quarter 2010 Financial Results and Reviews Accomplishments
[read more]Wednesday, November 03, 2010
Soligenix Receives Award Totaling $244,479 for orBec® Program from Qualifying Therapeutic Discovery Project
[read more]Tuesday, November 02, 2010
Soligenix Announces Completion of Enrollment and Preliminary Safety Results of a Phase 1B Clinical Trial for RiVax™
[read more]Monday, October 25, 2010
Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
[read more]Monday, September 27, 2010
Soligenix Provides Corporate Update
[read more]Wednesday, September 15, 2010
Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
[read more]Thursday, September 02, 2010
Soligenix Announces Publication of Article Identifying Domains Within the Ricin Toxin A Subunit as Targets of Protective Antibodies
[read more]Monday, August 23, 2010
Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
[read more]Friday, August 13, 2010
Soligenix Reports Second Quarter 2010 Financial Results and
Reviews Accomplishments
[read more]Tuesday, June 29, 2010
Soligenix to Present at the OneMedForum Conference
on Wednesday, June 30 at 2PM EDT
[read more]Friday, June 25, 2010
Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
[read more]Wednesday, June 16, 2010
Soligenix Announces Private Equity Financing of $5.16 Million with its Partner Sigma-Tau and other Institutional Investors
[read more]Thursday, June 03, 2010
Soligenix Announces Grant of European Patent for the Treatment of GVHD and Leukemia with Oral Beclomethasone Dipropionate
[read more]Wednesday, May 19, 2010
Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate
[read more]Monday, May 17, 2010
Soligenix Reports First Quarter 2010 Financial Results and
Reviews Accomplishments
[read more]Wednesday, May 12, 2010
Soligenix Announces Completion of Patient Enrollment
in Phase 2 Acute GVHD Prevention Clinical Trial
[read more]Monday, May 10, 2010
Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
[read more]Thursday, April 01, 2010
Soligenix Reports Year-End 2009 Financial Results and
Reviews Accomplishments
[read more]Wednesday, February 17, 2010
Soligenix Announces Issuance of Hong Kong Patent for its LPM™ Oral Drug Delivery Technology
[read more]Wednesday, February 03, 2010
Soligenix to Present at 12th Annual BIO CEO & Investor Conference
[read more]Tuesday, February 02, 2010
Soligenix Announces Publication of Positive Stability Results with RiVax™, its Vaccine Against Ricin Toxin
Preclinical Data Demonstrate the Potential for Long-term Stability of RiVax™ [read more]
